Amgen stock slips on annual outlook; Q4 results top estimates

February 05, 2025 09:07 PM AEDT | By Investing

Google News:

Amgen stock slips on annual outlook; Q4 results top estimates

Recent News

Soprano Strengthens Security Posture After Achieving SOC 2 Compliance

Origin Agritech Announced Financial Results for the Six Months Ended M...

CACI President and CEO John Mengucci Named ‘Executive of the Year’ by...

CNH’s Mentoring Initiative To Empower Students Experiencing Poverty

Amgen Inc (NASDAQ:AMGN) reported better-than-expected fourth-quarter results on Tuesday, but its shares fell 1.5% in premarket trading Wednesday as the company's profit outlook for 2025 fell short of analyst expectations.

The biotechnology giant posted adjusted earnings per share of $5.31, surpassing the analyst estimate of $5.04. Revenue for the quarter came in at $9.1 billion, exceeding the consensus estimate of $8.85 billion and representing an 11% increase YoY.

Despite the strong quarterly performance, investors appeared to focus on Amgen's guidance for fiscal year 2025. The company projects earnings per share between $20.00 and $21.20, with the midpoint of $20.60 falling below the analyst consensus of $20.82.

Full-year revenue is projected at $34.3 billion, slightly below the consensus estimate of $34.53 billion.

"AMGN posted a 4Q beat and 2025 rev/EPS guidance bracketed consensus, which we view as a positive given questions ahead of the quarter," Morgan Stanley (NYSE:MS) analysts commented in a post-earnings note.

The company's fourth-quarter product sales grew 11%, primarily driven by 14% volume growth. Excluding sales from the recently acquired Horizon Therapeutics (NASDAQ:HZNP), product sales increased 10%, fueled by 15% volume growth. Ten products, including Repatha, BLINCYTO, and TEZSPIRE, delivered at least double-digit sales growth in the quarter.

For the full year 2024, Amgen's total revenues increased 19% to $33.4 billion compared to 2023. Product sales grew 19%, driven by 23% volume growth, partially offset by 2% lower net selling price.

Robert A. Bradway, chairman and CEO of Amgen, commented on the results: "Robust growth in sales and earnings throughout 2024 reflects the momentum of our business. With strong performance globally, we are investing heavily in our rapidly advancing pipeline to deliver innovative therapies across our four therapeutic areas."

The company generated $10.4 billion of free cash flow for the full year, up from $7.4 billion in 2023, driven by business performance and timing of working capital items.

"2025 is another catalyst-rich year for Amgen and includes multiple overlooked inflection points for the pipeline and opportunities to drive the stock," TD Cowen analysts said in a post-earnings note.

Obesity remains a "key focus" for investors as MariTide moves into Phase 3 trials in the first half of 2025, analysts added,1with additional Phase 2 data expected later this year. Meanwhile, AMG 513 has encountered a setback with a Phase 1 clinical hold, though management remains confident the issue will be resolved, as they believe it is not drug-related.

This article first appeared in Investing.com

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.